CureSearch for Children’s Cancer has awarded $1 million to Dr. Yael Mossé of Children’s Hospital of Philadelphia to a promising new treatment for high-risk neuroblastoma, one of the most aggressive and difficult-to-treat childhood cancers.
Dr. Mossé’s research was selected through CureSearch’s Acceleration Initiative Award, a highly competitive grant that advances cutting-edge projects with the potential to quickly move from lab to clinic. Neuroblastoma is the most common solid tumor outside the brain in children, accounting for 8–10% of all childhood cancer diagnoses and roughly 15% of related deaths. Her work focuses on a precision treatment that targets cancer-driving mutations while sparing healthy tissue, with the goal of improving survival and reducing harmful side effects for young patients.
“This award provides an unprecedented opportunity to streamline the overall development of a novel therapy for patients with neuroblastoma by accelerating the entire drug development process. This translation of our science could not be possible without the support of CureSearch,” shares Dr. Mossé.
As federal research funding becomes increasingly uncertain, CureSearch is stepping in to ensure the most promising science moves forward, and that every child has access to safe, effective treatment.
This project is supported in part by the Norcross Foundation.
